IGIvane Gamkrelidze

Ivane Gamkrelidze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ivane Gamkrelidze has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Current Burden of Hepatitis B in the United States: A State, Territorial, and County Modelling Analysis

    by Devin Razavi‐Shearer, Ivane Gamkrelidze, Samantha Hall, Chari Cohen, Robert Gish, Thaddeus Pham, Kathryn Razavi‐Shearer, William Remak, Myriam Saboui, Alexis Voeller, et al.

    Accurate estimates of the prevalence of chronic hepatitis B virus (HBV) in the United States (US) are necessary for policy makers and community‐based organisations to make informed decisions regarding the allocation of resources to work towards the elimination of HBV as a public health threat. The primary aim of this study was to quantify the current HBV prevalence in the US at the state, county, and territorial level. The secondary aim was to quantify which countries of birth lead HBV infections. Using previously validated and published population‐based country level Markov models, the prevalence of HBV among immigrants in the US by country of birth was estimated in 2021. These estimates were then applied to county level population estimates from the 2018–2022 American Community Survey. This resulted in new county, state, territorial (Puerto Rico and Washington, D.C.), and national level HBV prevalence estimates. The total number of HBV infections in the US was estimated to be 1.7 million (UI: 795,000–4.1 million) corresponding to a prevalence of 0.50% (UI: 0.24%–1.23%). The state with the highest prevalence was Hawai‘i, 1.3% (UI: 0.5%–40%), while Wyoming was estimated to have the lowest prevalence, 0.2% (UI: 0.1%–1.1%). The largest number of total infections was found in California, 347,100 (UI: 193,700–729,200). The Aleutians West Census Area was the county with the highest prevalence, 2.9% (UI: 0.8%–9.7%), while Los Angeles County had the highest number of infections, 96,700 (UI: 54,800–190,600). These data can aid planners at all levels to better understand the complexities of HBV in the US. Thus, providing evidence for targeted public health interventions that will reduce the burden of HBV and improve the lives of those living with the disease.


  • Modelling Micro‐Elimination: Third‐Trimester Tenofovir Prophylaxis for Perinatal Transmission of Hepatitis B in the Remote Dolpa District of Nepal

    by Belaynew Taye, Patricia Valery, Shrestha Ananta, Sudhamshu Kc, Ivane Gamkrelidze, Devin Razavi‐Shearer, Homie Razavi, Paul Clark

    Hepatitis B (HBV) prevalence is very high in pregnant women in the Dolpa district of Nepal, a region characterised by a remote geographic landscape and low vaccination coverage. Using mathematical modelling, we evaluated the impact of third‐trimester tenofovir disoproxil fumarate (TDF) prophylaxis on HBV burden and estimated the time required to achieve HBV elimination in Dolpa. We developed a mathematical model to assess the impact of TDF prophylaxis on HBV elimination under four scenarios: baseline 50% vaccination coverage (scenario I ), 50% TDF and baseline vaccination coverage (scenario II ), 90% TDF plus baseline vaccination (scenario III ) and 90% TDF and birth‐dose plus 95% vaccination coverage (scenario IV ). We estimated the impact TDF prophylaxis has on HBV‐related morbidity and mortality and projected the time required for HBV elimination in the district. Our model suggests that HBV elimination is unlikely in Dolpa by 2100 under baseline interventions. The scale‐up of TDF coverage to 90% with the baseline vaccination significantly reduces HBV prevalence and HBV‐related mortality, making elimination possible in < 60 years. Implementing 90% TDF alongside birth‐dose vaccination and 95% infant HBV vaccination coverage could accelerate HBV elimination—≤ 0.1% HBV prevalence in children younger than 5 years–achieving it by 2045. In geographically inaccessible settings, a micro‐elimination approach using third‐trimester TDF is an effective and equitable strategy for HBV control. This approach is likely to substantially reduce HBV burden and HBV‐related mortality even before achieving elimination, while also addressing some of the challenges of immunoprophylaxis.

  • Open Access

    Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling study

    by Boshen Jiao, Ryoko Sato, Joshua Mak, Bryan Patenaude, Margaret de Villiers, Aniruddha Deshpande, Ivane Gamkrelidze, Katy A. M. Gaythorpe, Timothy B. Hallett, Mark Jit, et al.

    Background: Poverty alleviation is a major global development goal. Vaccines have the potential to provide financial risk protection (FRP) by preventing illnesses and associated healthcare costs. We estimate the lifetime FRP benefits generated by major vaccines among individuals vaccinated between 2000 and 2030 in low- and middle-income countries (LMICs). Methods and findings: We developed a microsimulation model to quantify the number of cases of catastrophic health expenditure (CHE) averted by a range of vaccines in 52 Gavi-eligible countries, stratified by wealth quintile. Vaccines protecting against five pathogens were considered, i.e., hepatitis B (routine and birth dose vaccine), Haemophilus influenzae type B, rotavirus, measles (routine and supplementary campaign vaccine), and Streptococcus pneumoniae . Model inputs were obtained from secondary data sources, including infection reduction rates under various immunization coverage scenarios, out-of-pocket health expenditures, transportation costs, wage losses, and healthcare utilization associated with disease treatment and consumption expenditures. CHE cases were defined as exceeding 10% of annual consumption, with sensitivity analyses conducted using thresholds of 25% and 40%, as well as impoverishing health expenditures were estimated. All vaccines, singly and collectively, showed a large impact on FRP and could avert ~200 million CHE cases across 52 Gavi-eligible countries from 2000 to 2030. Importantly, about half of all CHE cases were prevented among the poorest quintiles. When evaluated at a 10% threshold for CHE, the first dose of measles vaccine stood out in averting around 1,400 CHE cases per 10,000 vaccinated individuals in the poorest quintile, that is a total of 44 million CHE cases averted. A key limitation is the assumption of uniform disease risks in the absence of vaccination across quintiles, which may underestimate benefits for poorer groups. Conclusions: Vaccines can provide substantial FRP benefits, particularly among the most disadvantaged populations. Sustained investments to ensure vulnerable populations receive vaccinations in LMICs can therefore not only improve health outcomes but also contribute to poverty reduction.


  • Open Access

    Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study

    by Devin M. Razavi-Shearer, Loreta A. Kondili, Samantha Hall, Maria Buti, Ivane Gamkrelidze, Marcelo C.M. Naveira, Helen Nde, Francesco Negro, Andrea Osmani, Camila A. Picchio, et al.


  • Open Access

    Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States

    by Carolyn Wallace, Ivane Gamkrelidze, Chris Estes, Homie Razavi, Arun J. Sanyal


  • Open Access

    The Disease and Economic Burden of HBV and HCV in Ethiopia

    by Alexis S. Voeller, Asgeir Johannessen, Zebideru Zewdie Abebe, Wegene Adugna, Ivane Gamkrelidze, Eleni Seyoum, Lia Tadesse Gebremedhin, Mirtie Getachew Meselu, Seblewongel Abate Nigussie, Asmamaw Silesh, et al.

    As the second most populated country in Africa, Ethiopia needs public health measures to control diseases that impact its population. The goal of this study is to analyse disease burdens of HBV and HCV, while also highlighting their estimated associated costs for the country. A literature review and a Delphi process reflecting input of Ethiopian experts and the National Viral Hepatitis Technical Working Group were used to complement mathematical modelling to estimate HBV and HCV disease and economic burdens. Two scenarios were created for HCV: 2023 base and WHO elimination. For HBV, three scenarios were created: 2023 base, WHO elimination and universal birth dose. Using current country costs, each scenario was also examined through an economic lens. There were an estimated 7.6 million HBV infections in 2023. To impact transmission, a universal birth dose and pregnant women screening program would allow Ethiopia to vaccinate approximately 3.9 million infants annually, with a budget of $4.68 million USD, meeting the WHO prevalence elimination target (≤ 0.1% in ≤ 5‐year‐olds) by 2043. Ethiopia had an estimated 690,000 HCV infections in 2023. To achieve HCV elimination, the country would need to expand screening and treatment to 74,000 individuals annually with a peak budget of $12 million USD per year until 2032, decreasing to less than $2 million USD in 2035. Ethiopia can begin making steps towards elimination of HBV through expansion of birth dose vaccination. However, larger investments will be needed to scale‐up treatment and diagnosis interventions for both diseases.


  • Open Access

    The impact of immigration on hepatitis B burden in the United States: a modelling study

    by Devin Razavi-Shearer, Ivane Gamkrelidze, Calvin Q. Pan, Kathryn Razavi-Shearer, Sarah Blach, Chris Estes, Ellen Mooneyhan, Homie Razavi


  • Impacts of the Egyptian national screening and treatment programme for viral hepatitis C: A cost‐effectiveness model

    by Sameera Ezzat, Ivane Gamkrelidze, Alaa Osman, Asmaa Gomaa, Ayat Roushdy, Gamal Esmat, Homie Razavi, Sarah Blach, Wael Abdel‐Razek, Wafaa El‐Akel, et al.

    Background & Aims: Egypt used to have one of the highest prevalences of HCV infection worldwide. The Egyptian Ministry of Health launched a national campaign for the detection and management of HCV to reduce its burden. This study aims to carry out a cost‐effectiveness analysis to evaluate the costs and benefits of the Egyptian national screening and treatment programme.Methods: A disease burden and economic impact model was populated with the Egyptian national screening and treatment programme data to assess direct medical costs, health effects measured in disability‐adjusted life years and the incremental cost‐effectiveness ratio. The scenario was compared to a historical base case, which assumed that no programme had been conducted.Results: Total number of viremic cases is expected to decrease in 2030 by 86% under the national screening and treatment programme, versus by 41% under the historical base case. Annual discounted direct medical costs are expected to decrease from $178 million in 2018 to $81 million by 2030 under the historical base case, while annual direct medical costs are estimated to have peaked in 2019 at $312 million before declining to $55 million by 2030 under the national screening and treatment programme. Under the programme, annual disability‐adjusted life years are expected to decline to 127 647 by 2030, leading to 883 333 cumulative disability‐adjusted life years averted over 2018–2030.Conclusions: The national screening and treatment programme is highly cost‐effective by the year 2021, cost‐saving by 2029 and expected to save about $35 million in direct costs and $4705 million in indirect costs by 2030.


  • Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis

    by Ivane Gamkrelidze, Jean‐Michel Pawlotsky, Jeffrey V. Lazarus, Jordan J. Feld, Stefan Zeuzem, Yanjun Bao, Ana Gabriela Pires dos Santos, Yuri Sanchez Gonzalez, Homie Razavi

    BACKGROUND & AIMS: Elimination of HCV by 2030, as defined by the World Health Organization (WHO), is attainable with the availability of highly efficacious therapies. This study reports progress made in the timing of HCV elimination in 45 high‐income countries between 2017 and 2019.METHODS: Disease progression models of HCV infection for each country were updated with latest data on chronic HCV prevalence, and annual diagnosis and treatment levels, assumed to remain constant in the future. Modelled outcomes were analysed to determine the year in which each country would meet the WHO 2030 elimination targets.RESULTS: Of the 45 countries studied, 11 (Australia, Canada, France, Germany, Iceland, Italy, Japan, Spain, Sweden, Switzerland, and United Kingdom) are on track to meet WHO's elimination targets by 2030; five (Austria, Malta, Netherlands, New Zealand, and South Korea) by 2040; and two (Saudi Arabia and Taiwan) by 2050. The remaining 27 countries are not expected to achieve elimination before 2050. Compared to progress in 2017, South Korea is no longer on track to eliminate HCV by 2030, three (Canada, Germany, and Sweden) are now on track, and most countries (30) saw no change.CONCLUSIONS: Assuming high‐income countries will maintain current levels of diagnosis and treatment, only 24% are on track to eliminate HCV by 2030, and 60% are off track by at least 20 years. If current levels of diagnosis and treatment continue falling, achieving WHO's 2030 targets will be more challenging. With less than ten years remaining, screening and treatment expansion is crucial to meet WHO's HCV elimination targets.


  • Top Cited Papers

    Impact of COVID-19 on global HCV elimination efforts

    by Sarah Blach, Loreta A. Kondili, Alessio Aghemo, Zongzhen Cai, Ellen Dugan, Chris Estes, Ivane Gamkrelidze, Siya Ma, Jean-Michel Pawlotsky, Devin Razavi-Shearer, et al.